Treatment of Chronic Hepatitis C in Special Populations

被引：11

作者：

Bunchorntavakul, Chalermrat ^{[1
]}

Tanwandee, Tawesak ^{[2
]}

机构：

[1] Rangsit Univ, Coll Med, Rajavithi Hosp, Div Gastroenterol & Hepatol,Dept Internal Med, Bangkok 10400, Thailand

[2] Mahidol Univ, Siriraj Hosp, Fac Med, Div Gastroenterol & Hepatol,Dept Internal Med, Bangkok 10700, Thailand

来源：

GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2015年 / 44卷 / 04期

关键词：

Hepatitis C virus; Treatment; Decompensated cirrhosis; Liver transplantation; HIV coinfection; Chronic kidney disease; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT-EXPERIENCED PATIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; SEVERE RENAL IMPAIRMENT; DRUG-DRUG INTERACTIONS; GENOTYPE; INFECTION; LIVER-TRANSPLANTATION; HCV INFECTION; TREATMENT-NAIVE; VIRAL-HEPATITIS;

D O I：

10.1016/j.gtc.2015.06.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The management of hepatitis C virus (HCV) infection in special populations is challenging. The efficacy and safety data of the currently approved all-oral direct-acting antiviral combinations, including sofosbuvir, ledipasvir, daclatasvir, paritaprevir/ritonavir/ombitasvir plus dasabuvir (3D), and ribavirin, is compelling for use in special HCV populations, as has recently been recommended by expert guidelines. The treatment regimens and sustained virological response rates for special populations are nearly similar to those of the general HCV population. Sofosbuvir is not recommended in patients with severe renal impairment, and simeprevir and 3D regimen are not recommended for those with decompensated liver disease.

引用

页码：883 / +

页数：19

共 73 条

[1] Management of hepatitis C in patients with chronic kidney disease [J].